The latest human papillomavirus vaccine (HPV) could prevent 80 percent of cervical cancers in the United States, according to a recent study done by researchers at Cedars-Sinai Medical Center.

The new 9-valent HPV vaccine includes seven cancer causing HPV-types and has the potential to protect against nearly 19,000 other cancers diagnosed in the United States, including anal, oropharyngeal and penile cancers. This is in addition to protecting against 80 percent of cervical cancers, The Business Standard reported.

This is a 13 percent increase in protection against HPV-related cancers in comparison to the first vaccines on the market, Gardasil and Cervarix, which protected against HPV types 16 and 18.

According to medicalxpress.com, this is a 13 percent increase

"This is the first comprehensive study of its kind and shows the potential to not only reduce the global cancer burden, but also guide clinical decision-making with regard to childhood vaccinations," said Marc T. Goodman, PhD, MPH, senior author of the study and director of Cancer Prevention and Genetics at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute.

For the study, researchers examined nearly 3,000 HPV DNA tissue samples from seven population-based cancer registries.

They found that the new HPV vaccine also has the potential to protect against an additional 8 percent of oropharyngeal cancers, which include the base of the tongue and tonsils. This disease is the second-most-common HPV-associated cancer.

"We found that 70 percent of patient DNA tissue samples with cancer of the oropharynx harbored HPV," Goodman added. "This is a much higher percentage of HPV than observed in other studies, likely because of changes in sexual behaviors, such as increased oral-genital contact."

The findings are detailed in the JNCI Journal of the National Cancer Institute.